4Gershenson DM. Clinical management potential tumors of low malignancy[J]. Best Praet Res Clin Obstet Gynaecol, 2002,16 (4) :513-527. 被引量：1
5Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary[J]. Am J Clin Pathol, 2005,123 (Suppl) :S13-57. 被引量：1
6Valentin L, Jurkovic D, Van CB, et al. Adding a single CA125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses[J]. Ultrasound Obstet Gynecol, 2009,34 (3) : 345-354. 被引量：1
7Palomba S, Zupi E, Russo T, et al. Comparison of two fertility- sparing approaches for bilateral borderline ovarian tumors: a randomized controlled study[J]. Hum Reprod,2007,22(2) :578- 585. 被引量：1
8Hart WR. Borderline epithelial tumors of the ovary[J]. Mod Pathol,2005,18(2) :33-50. 被引量：1
9Grisham RN, BerekJ, Pfisterer J, et al. Abagovomab.. an anti- idiotypic CA125 targeted immunotherapeutic agent for ovarian cancer[J], lmmunothempy,2011,3(2) :153-162. 被引量：1
10Engelen MJ, deBruijn HW, Hollema H, et al. Serum CA125, carcinoembryonic antigen, and CA19-9 as tumor markers in borderline ovarian tumors[J]. Gynecol Oncol, 2000,78 (1): 16- 20. 被引量：1
